# Headsafe (full) > Headsafe builds technology that brings objective brain data into everyday care. Its flagship product, Nurochek™, is a portable, FDA-cleared brain assessment device used as an aid to the diagnosis of concussion that delivers objective brain function data in approximately two minutes, without requiring a baseline test. Site: https://headsafe.com Short version of this file: https://headsafe.com/llms.txt ## Company Headsafe Holdings, Inc. is an American MedTech company, incorporated in Delaware, and the parent company of the Headsafe Group (announced September 2, 2026). Founded in Sydney, Australia, where its clinical research roots remain, Headsafe now operates from the United States, its primary growth market. Its mission is to make concussion assessment faster, safer, and more consistent across points of care. With U.S. and global operations led by CEO Craig Corrance, Headsafe is focused on supporting real-world adoption through practical implementation, training, and clinical workflow integration. Timeline of announcements: - 2026-01-28 — Entered the U.S. healthcare market with the launch of Nurochek™; appointed Craig Corrance as Chief Executive Officer. https://headsafe.com/about/press/us-market-launch - 2026-02-16 — Interview with Craig Corrance on making objective concussion assessment routine care. https://headsafe.com/about/press/ceo-interview - 2026-03-31 — U.S. distribution partnership with Spartan Medical. https://headsafe.com/about/press/spartan-distribution - 2026-05-19 — Headsafe MFG Pty Ltd received a Medical Device Single Audit Program (MDSAP) Certificate of Registration from Intertek, confirming conformance to ISO 13485:2016 and supporting regulatory requirements for Australia and the United States. https://headsafe.com/about/press/mdsap-certification - 2026-09-02 — Established Headsafe Holdings, Inc. as the Delaware-incorporated U.S. parent company of the Headsafe Group. Announced distribution partners include Spartan Medical and 4U Solutions. https://headsafe.com/about/press/us-parent-company Offices: - U.S. headquarters: Headsafe US, Inc., Lake Mary, Florida 32746, USA. - Australia office: Headsafe MFG Pty Ltd, 76/61 Marlborough Street, Surry Hills NSW 2010, Australia. ## Nurochek™ — FDA indication for use 510(k) number: K243426. Source page: https://headsafe.com/nurochek/indications The Nurochek-Pro System is intended for prescription use in healthcare facilities for patients aged between 12 and 44 years old, for the aid in diagnosis of mild traumatic brain injury (mTBI) in conjunction with a standard neurological assessment. The Nurochek-Pro System is indicated for the generation of visual evoked potentials (VEP) and to acquire, transmit, display, and store electroencephalograms (EEG) during the generation of VEPs. Additionally, the system is indicated to analyze captured EEG signals to provide an aid in the diagnosis of mild traumatic brain injury (mTBI) in patients aged between 12 and 44 years old who have sustained a potential head injury in the past 120 hours (5 days). Use context: - To be used by or under the supervision of qualified healthcare professionals. - As an aid to diagnosis, in conjunction with standard neurological assessment. - To provide objective, quantitative brain function data to support clinical judgment. Contraindications and precautions: - History of epilepsy and/or seizures - Existing structural brain injury and/or condition - Legally blind - Open head wounds/breached skin in contacting areas ## How Nurochek™ works Nurochek™ uses electroencephalography (EEG) and visual evoked potentials to measure how the brain responds to controlled visual stimuli. A trained healthcare professional fits a lightweight headset, a guided software protocol runs the assessment, and built-in AI and machine learning algorithms analyze the signal to produce a clear, objective report that supports the clinician's decision. The test requires no baseline and takes about two minutes. Nurochek™ does not replace CT or MRI when structural injury is a concern, and it does not replace clinical judgment; it adds objective brain function data to the standard neurological assessment. Software platform: Windows 10 or 11. Settings where Nurochek™ is used: emergency departments, urgent care centers, neurology and concussion clinics, sports medicine (including certified athletic trainers), and imaging centers. ## Leadership (source: https://headsafe.com/about/leadership) - Craig Corrance — Chief Executive Officer. 3+ decades of global Orthopedic and MedTech industry experience with 2+ decades at C-suite level. Has led numerous companies through high growth to strategic exits. - Philip Gower — Chief Strategy & Commercial Officer. 18 years Healthcare / MedTech Entrepreneurial C-level roles (CEO, CSO, COO). Inc. 5000 award recipient for growth. Significant experience in SaaS and healthcare technology from product development to strategic exit. - Dylan Mahony — Chief Technology Officer. Biomedical Engineer and Neuroscientist with strong background in concussion research, quality systems and regulatory processes. - Dr. Kay Trippner — Chief Financial Officer. 20+ years experience corporate CFO and operational early-stage CEO. A serial tech and MedTech entrepreneur. - Rob Kukuljan — US Legal Counsel. Corporate Attorney. 30 years of experience in mergers and acquisitions, securities, corporate governance and commercial transactions. ## Board of directors (source: https://headsafe.com/about/leadership/board-of-directors) - Stephen Brimo — Chairman. 35+ years in investment banking as Managing Director at JPMorgan Chase and Credit Agricole CIB. Active early-stage investor in MedTech and technology, and experienced board member and adviser. - Greg Wilson — Company Secretary. 24 years as President of Neptune Pacific Direct Line, building a logistics business across 16 Pacific Island countries. Chairman of Pacific Forum Line. - Tony Dimun — Director. 40+ years in healthcare and medical devices. Former EVP and CFO of Vital Signs, Inc. (acquired by GE Medical for $1B). Has invested in 41 medical device companies through Nascent Enterprises. - Craig Corrance — Director and CEO. 3+ decades of global Orthopedic and MedTech industry experience with 2+ decades at C-suite level. Has led numerous companies through high growth to strategic exits. ## Frequently asked questions (source: https://headsafe.com/nurochek/faq) ### Clinical Q: What does Nurochek measure? A: Nurochek measures Visual Evoked Potentials (VEP) combined with EEG—the electrical signals generated by your brain in response to visual stimuli. The system analyzes over 400,000 data points using proprietary AI algorithms developed over 8 years of research. These objective measurements provide insight into brain function that subjective tests cannot capture. Q: Does Nurochek replace CT scans? A: No. Nurochek provides functional brain data that complements structural imaging like CT. CT scans are used to rule out bleeds and structural injuries; Nurochek provides objective functional assessment of brain activity. They serve different clinical purposes and Nurochek is intended to be used alongside—not instead of—standard neurological evaluation. Q: What is the age range for Nurochek? A: Nurochek is FDA-cleared for use in individuals aged 12 to 44 years old who have sustained a potential head injury within the past 120 hours (5 days). It is intended for use in conjunction with a standard neurological assessment. Q: Is Nurochek a diagnostic tool? A: Nurochek is FDA-cleared as an aid in the diagnosis of mild traumatic brain injury (mTBI/concussion). It provides objective, quantitative brain function data to support clinical judgment but does not replace comprehensive clinical evaluation. Diagnosis remains a clinical decision made by qualified healthcare professionals. ### Implementation Q: What training is required? A: Headsafe provides comprehensive training with every Nurochek purchase or lease. Training covers device operation, test administration, results interpretation, and integration into clinical workflows. Our team also provides ongoing support. Q: Is Nurochek reimbursable? A: CPT codes are available for Nurochek assessments. Our team can provide guidance on reimbursement, billing codes, and payer documentation requirements. Q: What support is available? A: Headsafe provides ongoing technical support, automatic software updates, and workflow guidance. Our Support Team is available to help with device operation, troubleshooting, and workflow integration. Q: How portable is the device? A: Nurochek is designed for true portability. The lightweight, reusable headset connects via USB to a PC-based application. The system fits easily in a standard medical bag, making it practical for use in ERs, urgent care centers, neurology clinics, sports medicine facilities, and sideline settings. ### Product Q: What is Nurochek? A: Nurochek is an FDA-cleared, portable brain assessment device that uses EEG and Visual Evoked Potential (VEP) technology to provide objective data supporting concussion diagnosis. It analyzes over 400,000 data points and delivers results in approximately 2 minutes—without requiring a pre-injury baseline. Q: How long does the assessment take? A: The Nurochek™️ test takes 2 minutes and 15 seconds (including rest). Depending on the ISP connection speed, the cloud based software result could take up to an additional 30 seconds. The total time of; minimal data entry into the software, qualifying questions (contraindications), headset placement and Nurochek test can take a total time of 5 minutes on average. Q: Does Nurochek require a baseline test? A: No. Unlike cognitive tests that require pre-injury baseline measurements, Nurochek does not require any prior testing. It can assess any patient within the cleared age range (12-44 years) who has sustained a potential head injury within the past 120 hours (5 days). Q: Who can administer the test? A: Nurochek can be administered by trained clinical staff, including nurses, athletic trainers, and other healthcare professionals. Comprehensive training is provided with purchase or lease to ensure consistent, reliable results. ## Contact - Email: info@headsafe.com - Phone: +1 877 NUR0CHK (1-877-687-0245) - Demo requests: https://headsafe.com/request-demo - Contact form: https://headsafe.com/contact - LinkedIn: https://www.linkedin.com/company/headsafenurochek/ ## Important use information Nurochek™ is FDA-cleared as an aid in the diagnosis of mild traumatic brain injury (mTBI, concussion) when used in conjunction with a standard neurological assessment. It is cleared for individuals ages 12 to 44 years old, within 120 hours (5 days) of a potential head injury, and is intended for prescription use in healthcare facilities or by healthcare professionals. Exclusion criteria apply, including seizure history, epilepsy, existing structural brain injuries, and legal blindness. Nurochek™ is not a standalone diagnostic device; all clinical decisions are made by qualified healthcare professionals in conjunction with other clinical findings.